NasdaqGM - Delayed Quote USD

Aurinia Pharmaceuticals Inc. (AUPH)

8.07
-0.12
(-1.47%)
At close: May 19 at 4:00:01 PM EDT
8.08
+0.01
+(0.12%)
After hours: May 19 at 5:11:11 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
247,295
235,133
175,513
134,030
45,605
Cost of Revenue
29,070
28,248
14,148
5,664
1,091
Gross Profit
218,225
206,885
161,365
128,366
44,514
Operating Expense
169,856
188,466
253,056
239,836
225,249
Operating Income
48,369
18,419
-91,691
-111,470
-180,735
Net Non Operating Interest Income Expense
11,394
12,135
14,222
5,118
529
Other Income Expense
-17,956
-23,106
--
--
--
Pretax Income
41,807
7,448
-77,469
-106,352
-180,206
Tax Provision
1,962
1,696
551
1,828
760
Net Income Common Stockholders
39,845
5,752
-78,020
-108,180
-180,966
Diluted NI Available to Com Stockholders
39,845
5,752
-78,020
-108,180
-180,966
Basic EPS
0.27
0.04
-0.54
-0.76
-1.40
Diluted EPS
0.27
0.04
-0.54
-0.76
-1.40
Basic Average Shares
141,783
143,057
143,236
141,915
129,369
Diluted Average Shares
144,920
146,194
143,236
141,915
129,369
Total Operating Income as Reported
30,413
-4,687
-91,691
-111,470
-180,735
Total Expenses
198,926
216,714
267,204
245,500
226,340
Net Income from Continuing & Discontinued Operation
39,845
5,752
-78,020
-108,180
-180,966
Normalized Income
56,958.33
23,589.83
-78,020
-108,180
-180,966
Interest Income
16,013
16,970
16,997
5,118
529
Interest Expense
4,619
4,835
2,775
0
0
Net Interest Income
11,394
12,135
14,222
5,118
529
EBIT
46,426
12,283
-74,694
-106,352
-180,206
EBITDA
65,880
31,728
-63,047
-103,646
-177,445
Reconciled Cost of Revenue
29,070
28,248
14,148
5,664
1,091
Reconciled Depreciation
19,454
19,445
11,647
2,706
2,761
Net Income from Continuing Operation Net Minority Interest
39,845
5,752
-78,020
-108,180
-180,966
Total Unusual Items Excluding Goodwill
-17,956
-23,106
0
0
--
Total Unusual Items
-17,956
-23,106
0
0
--
Normalized EBITDA
83,836
54,834
-63,047
-103,646
-177,445
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-842.67
-5,268.17
0
0
0
12/31/2021 - 9/3/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AGEN Agenus Inc.
3.7900
+8.91%
 
ARWR Arrowhead Pharmaceuticals, Inc.
15.74
+0.19%
 
TGTX TG Therapeutics, Inc.
34.98
+1.80%
 
AXSM Axsome Therapeutics, Inc.
108.30
+0.72%
 
ARDX Ardelyx, Inc.
4.0600
+4.64%
 
AVXL Anavex Life Sciences Corp.
8.44
+1.44%
 
KPTI Karyopharm Therapeutics Inc.
5.13
-3.67%
 
ALT Altimmune, Inc.
5.50
-1.43%
 
SGMO Sangamo Therapeutics, Inc.
0.4985
+6.06%
 
SRRK Scholar Rock Holding Corporation
30.16
-1.28%